P-GEMOX方案一线治疗原发鼻外鼻型NK/T细胞淋巴瘤临床观察  

Clinical observation of primary extranasal nasal-type NK/T cell lymphoma treated with P-GEMOX as a first-line regimen

作　　者：胡丽娜 谢勉 李国强 冯春 柯鹏 张新友[1] 周继豪[1] Hu Lina;Xie Mian;Li Guoqiang;Feng Chun;Ke Peng;Zhang Xinyou;Zhou Jihao(Department of Hematology,the Second Clinical Medical College of Jinan University,Shenzhen People's Hospital,Shenzhen 518000,China;Department of General Practice,Shenzhen People's Hospital,the Second Clinical Medical College of Jinan University,Shenzhen 518000,China)

机构地区：[1]暨南大学第二临床医学院,深圳市人民医院血液内科,518000 [2]暨南大学第二临床医学院,深圳市人民医院全科医学科,518000

出　　处：《白血病．淋巴瘤》2020年第3期160-164,共5页Journal of Leukemia & Lymphoma

基　　金：深圳市人民医院"三名工程"临床研究培育项目(SYLY201722)。

摘　　要：目的探讨以P-GEMOX(培门冬酶、吉西他滨、奥沙利铂)方案作为一线方案治疗原发鼻外鼻型NK/T细胞淋巴瘤(NKTCL)的临床疗效。方法回顾性分析深圳市人民医院2015年9月至2018年10月收治的一线接受P-GEMOX方案化疗的7例原发鼻外鼻型NKTCL患者的临床表现、治疗反应及预后。结果7例原发鼻外鼻型NKTCL患者中位发病年龄41岁(27~74岁),男性多见(6例);原发及侵犯的鼻外部位包括回盲部、淋巴结、皮肤、睾丸、肾上腺、中枢神经系统等。患者一线采用P-GEMOX方案化疗,虽部分患者能获得短暂疗效,但最终所有患者均快速进展并死亡,总生存期2周至21个月。结论P-GEMOX方案一线治疗原发鼻外的鼻型NKTCL近期疗效尚可,但远期疗效较差。Objective To investigate the clinical efficacy of P-GEMOX(pegaspargase,gemcitabine and oxaliplatin)as a first-line regimen for the treatment of primary extranasal nasal-type NK/T cell lymphoma(NKTCL).Methods The clinical manifestations,treatment response and prognosis of 7 patients with primary extranasal nasal-type NKTCL who underwent P-GEMOX chemotherapy as a first-line therapy in Shenzhen People's Hospital from September 2015 to October 2018 were retrospectively analyzed.Results The median age of 7 patients with primary extranasal nasal-type NKTCL was 41 years old(27-74 years old),which was more commonly found in males(6 cases);the primary and invading extranasal sites included ileocecal,lymph nodes,skin,testis,adrenal gland,central nervous system,etc.The P-GEMOX regimen was used as a first-line therapy,although some patients had a short-term effect,all patients eventually progressed rapidly and died.The overall survival time was 2 weeks to 21 months.Conclusion The short-term efficacy of P-GEMOX as a first-line therapy for the treatment of primary extranasal nasal-type NKTCL is acceptable,but the long-term efficacy is poor.

关 键 词：淋巴瘤 NK/T细胞 鼻外 抗肿瘤联合化疗方案 P-GEMOX方案 

分 类 号：R733[医药卫生—肿瘤]